2021 Coffey-Holden
Prostate Cancer Academy Meeting

Prostate Cancer Research in the 21st Century

June 24 - 25, 2021

Program Organizing Committee:
Jelani Zarif, PhD, Committee Chair (Johns Hopkins University)
Joshua Russo, MD, PhD (Harvard: Beth Israel Deaconess Medical Center (BIDMC)
Samir Zaidi, MD, PhD (Memorial Sloan Kettering Cancer Center)
Di Zhao, PhD (The University of Texas MD Anderson Cancer Center)
Robert Flavell, MD, PhD (University of California, San Francisco)
Shuang George Zhao, MD (University of Wisconsin)
Catherine Coombs, MD (University of North Carolina, Chapel Hill)
Kenneth Pienta, MD (Johns Hopkins University)
Howard Soule, PhD (Prostate Cancer Foundation)
Andrea Miyahira, PhD (Prostate Cancer Foundation)
**Session I: Introduction**

7:00 AM – 7:10 AM  
**Welcome and Opening Remarks**  
*Stuart Holden, MD*  
Prostate Cancer Foundation; University of California, Los Angeles

7:10 AM – 7:40 AM  
**The Big Questions**  
*Kenneth Pienta, MD*  
Johns Hopkins University

**Session II: Clonal Hematopoiesis**

Session Chair:  
*Catherine Coombs, MD*  
University of North Carolina, Chapel Hill

7:40 AM – 7:45 AM  
**Plasma cfDNA Analysis Reveals Clonal Hematopoiesis as a Major Source of Somatic Mutations**  
*Pedram Razavi, MD, PhD*  
Memorial Sloan Kettering Cancer Center

7:45 AM – 7:55 AM  
Discussion  
First Question: Heather Cheng, MD, PhD

7:55 AM – 8:00 AM  
**The Impact of Cancer Therapy on Clonal Hematopoiesis and Risk of Secondary Leukemia**  
*Kelly Bolton, MD, PhD*  
Washington University in St Louis

8:00 AM – 8:10 AM  
Discussion  
First Question: Sarah Amend, PhD
Session III: Emerging Signaling Pathways in mCRPC

Session Chair: Di Zhao, PhD
The University of Texas MD Anderson Cancer Center

8:10 AM – 8:15 AM Targeting the AR/Integrin a6b1 Axis in CRPC
Cindy K. Miranti, PhD
University of Arizona Cancer Center

8:15 AM – 8:25 AM Discussion
First Question: Akash Patnaik, MD, PhD

8:25 AM – 8:30 AM Chromosomal Instability and cGAS-STING: Friend or Foe?
Samuel Bakhoum, MD, PhD
Memorial Sloan Kettering Cancer Center

8:30 AM – 8:40 AM Discussion
First Question: Janielle Maynard, PhD

8:40 AM – 8:45 AM Targeting Autophagy Potentiates Immune Checkpoint Blockade in Prostate Cancer Therapy
Yuanyuan Qiao, PhD
University of Michigan

8:45 AM – 8:55 AM Discussion
First Question: Nima Sharifi, MD

8:55 AM – 9:00 AM Ferroptosis and Prostate Cancer
Scott J. Dixon, PhD
Stanford University

9:00 AM – 9:10 AM Discussion
First Question: Sumit Subudhi, MD, PhD

9:10 AM – 9:15 AM The Functional Role of Tumor Stroma in Cancer Progression
Raghu Kalluri, MD, PhD
The University of Texas MD Anderson Cancer Center

9:15 AM – 9:25 AM Discussion
First Question: Rana McKay, MD
**Session IV: Wnt Signaling and the Challenges of Targeted Therapy**

**Session Chair:** Joshua Russo, MD, PhD  
Harvard: Beth Israel Deaconess Medical Center (BIDMC)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Institution/Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:25 AM – 9:30 AM</td>
<td>Wnt Signaling Drives Distinct Pathways in Primary and Metastatic Prostate Cancer</td>
<td>Steven Balk, MD, PhD</td>
<td>Harvard: Beth Israel Deaconess Medical Center</td>
</tr>
<tr>
<td>9:30 AM – 9:40 AM</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>First Question: Adam Sharp, MD, PhD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:40 AM – 9:45 AM</td>
<td>Precision Therapeutics for Lethal mCRPC: The Case for DKK1</td>
<td>David Wise, MD, PhD</td>
<td>New York University</td>
</tr>
<tr>
<td>9:45 AM – 9:55 AM</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>First Question: Xiao Wei, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:55 AM – 10:00 AM</td>
<td>Pre-Clinical Studies for Advancing Cirmtuzumab-Based Anti-ROR1 Therapies in Metastatic Prostate Cancer</td>
<td>Christina Jamieson, PhD</td>
<td>University of California San Diego, Moores Cancer Center</td>
</tr>
<tr>
<td>10:00 AM – 10:10 AM</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>First Question: Jimmy Zhao, MD, PhD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:10 AM – 10:15 AM</td>
<td>Targeting Hyperactive Wnt in Colon and Prostate Cancer</td>
<td>Lukas Dow, PhD</td>
<td>Weill Cornell Medicine</td>
</tr>
<tr>
<td>10:15 AM – 10:25 AM</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>First Question: Veronica Rodriguez-Bravo, PhD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:25 AM – 10:30 AM</td>
<td>Strategies to Mitigate Bone Toxicity when Targeting Wnt/B-Catenin Signaling</td>
<td>Bart Williams, PhD</td>
<td>Van Andel Institute</td>
</tr>
<tr>
<td>10:30 AM – 10:40 AM</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>First Question: Salma Kaochar, PhD, MFA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Keynote Lecture:
10:40 AM – 11:20 AM

Neuroendocrine Cell Plasticity and Anti-Tumor Immunity
David Barbie, MD
Harvard: Dana-Farber Cancer Institute

Discussion
11:20 AM – 11:40 AM
First Question: Jessica Hawley, MD

END OF DAY 1
7:00 AM – 7:05 AM  Welcome & Opening Remarks  
Jelani Zarif, PhD  
Organizing Committee Chair, 2021 Coffey-Holden Prostate Cancer Academy Meeting; Johns Hopkins University

**Session V: Cancer Immunotherapy and Synergizers**  
Session Chair: Jelani Zarif, PhD  
Johns Hopkins University

7:05 AM – 7:10 AM  Targeting MYC to Enhance Immunotherapy  
Sarki Abdulkadir, MD, PhD  
Northwestern University School of Medicine

7:10 AM – 7:20 AM  Discussion  
First Question: Nikki Delk, PhD

7:20 AM – 7:25 AM  Elucidating Mechanisms by which Racial Differences Impact Drug Responsiveness and Anti-Tumor Immunity  
Tonya Webb, PhD  
University of Maryland School of Medicine

7:25 AM – 7:35 AM  Discussion  
First Question: Jeremie Calais, MD

7:35 AM – 7:40 AM  Truncated O-Glycans as Immunotherapy Targets and Mediators of Immunosuppression in Prostate Cancer  
Avery Posey, PhD  
University of Pennsylvania

7:40 AM – 7:50 AM  Discussion  
First Question: Lorelei Mucci, ScD

7:50 AM – 7:55 AM  Unexpected Targets and Biomarkers of Checkpoint Immunotherapy  
Vassiliki A. Boussiotis, MD, PhD  
Harvard: Beth Israel Deaconess Medical Center

7:55 AM – 8:05 AM  Discussion  
First Question: Amina Zoubeidi, PhD
Session VI: Mediators of Plasticity using Functional Genomic Approaches

Session Chair: Samir Zaidi, MD, PhD
Memorial Sloan Kettering Cancer Center

8:05 AM – 8:10 AM
Identification and Functional Characterization of High–Plasticity Cancer Cell States
Tuomas Tammela, MD, PhD
Memorial Sloan Kettering Cancer Center

8:10 AM – 8:20 AM
Discussion
First Question: Isla Garraway, MD, PhD

8:20 AM – 8:25 AM
Shifting Transcriptional Vulnerabilities Beyond Androgen Therapy Exhaustion
Rohit Bose, MD, PhD
University of California, San Francisco

8:25 AM – 8:35 AM
Discussion
First Question: Mehmet Bilen, MD

8:35 AM – 8:40 AM
Understanding Androgen Deprivation Induced Lineage Plasticity: Leveraging New and Old Models Systems
Wouter Karthaus, PhD
Memorial Sloan Kettering Cancer Center

8:40 AM – 8:50 AM
Discussion
First Question: Huihui Ye, MD

8:50 AM – 8:55 AM
Targeting Critical Epigenetic Factors that Promote Prostate Cancer Lineage Plasticity
Joshi Alumkal, MD
University of Michigan

8:55 AM – 9:05 AM
Discussion
First Question: Ayesha Shafi, PhD

9:05 AM – 9:10 AM
MYC Drives Aggressive Prostate Cancer by Disrupting Transcriptional Pause Release at Androgen Receptor Targets
David P. Labbé, PhD
McGill University

9:10 AM – 9:20 AM
Discussion
First Question: Arianna Giacobbe, PhD
Session VII: Cancer Genomics & Sequencing
Session Chair: Shuang George Zhao, MD
University of Wisconsin

9:20 AM – 9:25 AM  Emerging Opportunities at the Interface of Clinical Computational Oncology and Prostate Cancer
Eliezer Van Allen, MD
Harvard: Dana-Farber Cancer Institute

9:25 AM – 9:35 AM  Discussion
First Question: Lucia Nappi, MD, PhD

9:35 AM – 9:40 AM  Using Functional Genomics Approaches to Interrogate Molecular Drivers of Prostate Cancer
Felix Feng, MD
University of California, San Francisco

9:40 AM – 9:50 AM  Discussion
First Question: Stephanie Harmon, PhD

9:50 AM – 9:55 AM  Plasticity in Neuroendocrine Prostate Cancer
Himisha Beltran, MD
Harvard: Dana-Farber Cancer Institute

9:55 AM – 10:05 AM  Discussion
First Question: Gail Prins, PhD

Session VIII: Imaging the Tumor Microenvironment and Metabolism
Session Chair: Robert Flavell, MD, PhD
University of California, San Francisco

10:05 AM – 10:10 AM  Image Habitats in Prostate Cancer
Yoganand Balagurunathan, PhD
Moffitt Cancer Center

10:10 AM – 10:20 AM  Discussion
First Question: Rebecca Graff, ScD

10:20 AM – 10:25 AM  Capturing the First In Vivo Measurements of the Labile Iron Pool with PET to Understand its Potential as a Theranostic Target in Prostate Cancer
Michael Evans, PhD
University of California, San Francisco

10:25 AM – 10:35 AM  Discussion
First Question: Adam Sowalsky, PhD
10:35 AM – 10:40 AM  
**Hyperpolarized $^{13}$C Metabolic Imaging of Metastatic Prostate Cancer – Current Status and Next Steps**  
*John Kurhanewicz, PhD*  
University of California, San Francisco

10:40 AM – 10:50 AM  
**Discussion**  
First Question: Susan Logan, PhD

10:50 AM – 10:55 AM  
**Metabolic Imaging of Prostate Cancer**  
*Kayvan Keshari, PhD*  
Memorial Sloan Kettering Cancer Center

10:55 AM – 11:05 AM  
**Discussion**  
First Question: Ana Aparicio, MD

11:05 AM – 11:10 AM  
**Imaging Tumor-Infiltrating CD8 Lymphocytes using ImmunoPET**  
*Anna Wu, PhD*  
City of Hope

11:10 AM – 11:20 AM  
**Discussion**  
First Question: Christopher Barbieri, MD, PhD

---

**Session IX: Closing Remarks**

11:20 AM – 11:35 AM  
**Meeting Debrief**  
*Kenneth Pienta, MD*  
Johns Hopkins University  
*Howard Soule, PhD*  
Prostate Cancer Foundation

---

END OF DAY 2